Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
Johnson and Johnson
QuintilesIMS
Mallinckrodt
Chubb

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,967,208

« Back to Dashboard

Which drugs does patent 6,967,208 protect, and when does it expire?

Patent 6,967,208 protects ELIQUIS and is included in one NDA.

This patent has seventy-two patent family members in thirty-five countries.

Summary for Patent: 6,967,208
Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s): Pinto; Donald J. P. (Churchville, PA), Quan; Mimi L. (Yardley, PA), Orwat; Michael J. (New Hope, PA), Li; Yun-Long (Wilmington, DE), Han; Wei (Yardley, PA), Qiao; Jennifer X. (Princeton, NJ), Lam; Patrick Y. S. (Chadds Ford, PA), Koch; Stephanie L. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:10/245,122
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,967,208
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,967,208
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,967,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCING THE RISK OF STROKE ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF PULMONARY EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,967,208

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037092 ➤ Sign Up
Argentina 067965 ➤ Sign Up
Austria 439360 ➤ Sign Up
Austria 544750 ➤ Sign Up
Australia 2002341693 ➤ Sign Up
Australia 2008207537 ➤ Sign Up
Brazil 0212726 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Covington
Chubb
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.